MIAMI — At the inaugural CEDARS/ASPENS meeting here, Quentin B. Allen, MD, reviews a panel discussion of the complex decision making that goes into IOL selection in challenging cases. In this case, a 75-year-old woman with cataracts was seeking a combination of multifocal lens and laser vision correction. She presented with hyperopia, pseudoexfoliation and a traumatically dilated pupil.
Physician-researchers with Bascom Palmer Eye Institute, part of UHealth – the University of Miami Health System, have found a link between “dry eye” and chronic pain syndromes – a finding that…
Clearside Biomedical enrolled its first patient for the phase 3 clinical trial of CLS-TA to treat macular edema associated with noninfectious uveitis, according to a company press release.The phase 3 Peachtree clinical trial to evaluate efficacy of 4 m…
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical biopharmaceutical company developing drugs for the eye, announces last patient enrolled in Phase 2 trial for macular edema associated with retinal vein occlusion.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from a Phase 2 exploratory clinical trial designed to evaluate a range of objective and subjective measures (signs and symptoms, respectively) for DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot for the treatment of inflammatory dry
Retinopathy of prematurity is a disease in premature infants who today, secondary to advanced neonatal intensive care units, are surviving at ever lower birth weights and weeks of gestation. These infants almost universally require oxygen supplementati…